首页 > 期刊列表> Oncology and Therapy

Oncology and Therapy

浏览量1853
分享 分享
微信好友 朋友圈 QQ好友 复制链接
订阅订阅 查看最新文献查看最新文献
WOS期刊分区 历年影响因子 历年发表 投稿信息 同类期刊
Oncology and Therapy
影响因子:
期刊影响因子(Impact factor,IF) 即某刊平均每篇论文的被引用数,是表征期刊影响大小的一项定量指标,它实际上是某刊在某年被全部源刊物引证该刊前两年发表论文的次数,与该刊前两年所发表的全部源论文数之比。
3.2 反馈 反馈
ISSN:
ISSN是由8个数字组成的编码,旨在识别各种报纸、专业杂志、画报、期刊,无论其性质或载体版本(纸版及电子版)。
print: 2366-1070
on-line: 2366-1089
研究领域:
ONCOLOGY
自引率:
0.00%
Gold OA文章占比:
Gold OA文章占比是指一个总体中金色OA文章数量占总体文章数量的比重。OA期刊的文章主要通过金色通道(Gold road,也称为Gold OA,即期刊官网)和绿色通道(Green road,或Green OA)实现开放获取。金色通道是开放获取期刊通过自己的官网来实现的,而绿色通道是通过把文章自存档于机构知识库(Institutional Repositories,比如哈佛大学学术库DASH)或学科知识库中来实现。
100.00%
原创研究文献占比:
64.52%
SCI收录类型:
Emerging Sources Citation Index (ESCI) || Directory of Open Access Journals (DOAJ)
期刊官网:
期刊介绍英文:
Now indexed in PubMed Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital features and plain language summaries Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Oncology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0 Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Open Access All articles published by Oncology and Therapy are published open access Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.
CiteScore:
引用分数(英语:CiteScore,CS)是一种用来反映学术期刊最近发表文章“年平均被引用次数”的衡量指标。该指标由Elsevier于 2016 年 12 月推出,以替代常用的JCR影响因子(由Clarivate计算)。 CiteScore是Scopus中系列期刊指标的一部分,包括 SNIP(源文档标准化影响),SJR (SClmago杂志排名),引用文档计数以及引用百分比。
CiteScoreSJRSNIPCiteScore排名
3.40.8980.883
学科
排名
百分位
大类:Medicine
小类:Oncology
236 / 404
41%

发文信息

WOS期刊分区

WoS-JCR分区:SCIE、SSCI收录期刊主要按影响因子高低被分为四个区(Quartile),分别是Q1区,Q2区,Q3区,Q4区,各占25%。Q1区是影响因子最靠前25%的期刊,Q4区是靠后的25%的期刊。
学科分类
Q2ONCOLOGY

历年影响因子

2022年2023年
2.70003.2000

历年发表

年文章数是指每年6月SCI发布的IF数据中所提供的上一年全年发文数量。如2018年7月-2019年6月,显示的是2017年的发文数.对极少数热门期刊,我们会在1月份更新为最新一年的发文数。
2016年2017年2018年2019年2020年2021年2022年
23181516274531

投稿信息

出版周期:
2 issues per year
出版语言:
English
出版国家(地区):
United Kingdom
初审时长:
3 days
审稿时长:
6 weeks
投稿网址:
出版商:
Adis, Springer Healthcare
PubMed链接:

同类期刊

JCO Global Oncology
JCO Global Oncology
APSIPA Transactions on Signal and Information Processing
APSIPA Transactions on Signal and Information Processing
Journal of Accounting in Emerging Economies
Journal of Accounting in Emerging Economies
Echo Research and Practice
Echo Research and Practice
Head & Neck Pathology
Head & Neck Pathology
High-Confidence Computing
High-Confidence Computing

Oncology and Therapy - 最新文献

查看全部

Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift.

Pub Date : 2024-12-01 DOI: 10.1007/s40487-024-00298-z Emanuela Palmerini, Giuliano Peta, Gianmarco Tuzzato

A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma.

Pub Date : 2024-12-01 DOI: 10.1007/s40487-024-00304-4 Diana Rofail, Anna Ciesluk, Teya Lovell, Patrick Marquis, Matthew G Fury, Chieh-I Chen
免责声明:
本页显示期刊或杂志信息,仅供参考学习,不是任何期刊杂志官网,不涉及出版事务,特此申明。如需出版一切事务需要用户自己向出版商联系核实。若本页展示内容有任何问题,请联系我们,邮箱:info@booksci.cn,我们会认真核实处理。
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1